Skip to main content
Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
97.50
+1.50 (1.56%)
Aug 15, 2025, 4:08 PM HKT

Innovent Biologics Revenue

In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.

Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
16.66
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
166.99B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20249.42B3.22B51.82%
Dec 31, 20236.21B1.65B36.21%
Dec 31, 20224.56B286.65M6.71%
Dec 31, 20214.27B425.91M11.08%
Dec 31, 20203.84B2.80B266.94%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
BeOne Medicines 35.81B
Hansoh Pharmaceutical Group Company 13.05B
JD Health International 71.34B
Akeso 2.26B
Sino Biopharmaceutical 30.72B
WuXi Biologics 19.87B
CSPC Pharmaceutical Group 28.99B
Sichuan Kelun-Biotech Biopharmaceutical 2.06B
Revenue Rankings

Innovent Biologics News

More News